| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BBRC.2005.11.072 |
| P698 | PubMed publication ID | 16316628 |
| P50 | author | Hideki Enokida | Q90787285 |
| P2093 | author name string | Masayuki Nakagawa | |
| Kenryu Nishiyama | |||
| Hiroyuki Kubo | |||
| Takenari Gotanda | |||
| Motoshi Kawahara | |||
| Ken Kawamoto | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P1104 | number of pages | 7 | |
| P304 | page(s) | 790-796 | |
| P577 | publication date | 2005-11-22 | |
| P1433 | published in | Biochemical and Biophysical Research Communications | Q864228 |
| P1476 | title | p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. | |
| P478 | volume | 339 |
| Q42364210 | Aberrant methylation of CDH11 predicts a poor outcome for patients with bladder cancer |
| Q34171782 | Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer |
| Q37598439 | Biological significance of promoter hypermethylation of p14/ARF gene: relationships to p53 mutational status in Tunisian population with colorectal carcinoma |
| Q37770780 | Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium |
| Q26744146 | Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer? |
| Q35027361 | Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice |
| Q39690220 | Comparison of the inhibitory effects of three transcriptional variants of CDKN2A in human lung cancer cell line A549. |
| Q35623184 | DNA Methylation and Flavonoids in Genitourinary Cancers |
| Q43292667 | Determination of DNA methylation by COBRA: a comparative study of CGE with LIF detection and conventional gel electrophoresis |
| Q37451558 | Epigenetic biomarkers in urothelial bladder cancer |
| Q37243940 | Epigenetics in bladder cancer |
| Q36675078 | Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging |
| Q42221192 | Genotyping of high-risk human papillomaviruses in p16/Ki-67-positive urothelial carcinoma cells: even a worm will turn |
| Q37978544 | Hypermethylation in bladder cancer: biological pathways and translational applications |
| Q83269158 | Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine |
| Q39205970 | Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis. |
| Q41834670 | Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing |
| Q46795145 | Methylation-dependent fragment separation: novel analysis of 5-methyl cytosine by capillary electrophoresis of amplified DNA using PCR incorporation of chemically modified dCTP. |
| Q37025942 | Molecular markers for bladder cancer: the road to a multimarker approach |
| Q43649454 | P14ARF deficiency and its correlation with overexpression of p53/MDM2 in sporadic vestibular schwannomas |
| Q43238966 | Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study |
| Q45040366 | Promoter hypermethylation of tumour suppressor genes (p14/ARF and p16/INK4a): case-control study in North Indian population. |
| Q90529098 | Promoter methylation analysis of CDH1 and p14ARF genes in patients with urothelial bladder cancer |
| Q28253632 | Promoter methylation and loss of p16(INK4a) gene expression in head and neck cancer |
| Q35533826 | Quantification of epigenetic biomarkers: an evaluation of established and emerging methods for DNA methylation analysis |
| Q33548990 | Quantitative detection of DNA methylation states in minute amounts of DNA from body fluids |
| Q35124821 | Quantitative gene analysis of methylation and expression (Q-GAME) in fresh or fixed cells and tissues |
| Q46827905 | Quantitative profiling of CpG island methylation in human stool for colorectal cancer detection |
| Q52582577 | Regulatory Network of ARF in Cancer Development. |
| Q36170604 | The Correlation Relationship between P14ARF Gene DNA Methylation and Primary Liver Cancer |
| Q34785439 | The Prognostic Value of p16 Hypermethylation in Cancer: A Meta-Analysis |
| Q53240641 | The inhibitory effect of intravesical fisetin against bladder cancer by induction of p53 and down-regulation of NF-kappa B pathways in a rat bladder carcinogenesis model. |
| Q36492827 | The relationship between promoter methylation of p16 gene and bladder cancer risk: a meta-analysis |
| Q36879301 | Therapeutic targets in the ARF tumor suppressor pathway. |
| Q38436074 | Tp53 and its potential therapeutic role as a target in bladder cancer |
| Q55056740 | Truncated Isoforms of lncRNA ANRIL Are Overexpressed in Bladder Cancer, But Do Not Contribute to Repression of INK4 Tumor Suppressors. |
| Q84021943 | [Value of biomarkers in urology] |
| Q86887079 | p16 INK4a overexpression and p16/Ki-67 dual labeling versus conventional urinary cytology in the evaluation of urothelial carcinoma |
| Q54481739 | p16(INK4a) /Ki-67 dual labelling as a marker for the presence of high-grade cancer cells or disease progression in urinary cytopathology. |
| Q42203359 | p16(INK4a) overexpression is not linked to oncogenic human papillomaviruses in patients with high-grade urothelial cancer cells |
| Q38375231 | p16/Ki-67 dual labeling and urinary cytology results according to the New Paris System for Reporting Urinary Cytology: Impact of extended follow-up |
Search more.